Adherex Technologies (FENC) Expected to Announce Earnings on Monday

Adherex Technologies (NASDAQ:FENC) is expected to be posting its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect Adherex Technologies to post earnings of $0.01 per share and revenue of $14.7330 million for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, March 25, 2026 at 9:30 AM ET.

Adherex Technologies Stock Down 2.9%

Shares of Adherex Technologies stock opened at $7.70 on Friday. The firm’s 50 day moving average price is $7.94 and its 200-day moving average price is $8.25. Adherex Technologies has a 52-week low of $4.68 and a 52-week high of $9.92. The company has a market cap of $263.49 million, a P/E ratio of -33.48 and a beta of 0.75.

Insider Buying and Selling

In related news, major shareholder Southpoint Capital Advisors Lp sold 1,000,000 shares of Adherex Technologies stock in a transaction on Wednesday, December 24th. The shares were sold at an average price of $7.50, for a total value of $7,500,000.00. Following the sale, the insider owned 2,744,741 shares of the company’s stock, valued at approximately $20,585,557.50. This trade represents a 26.70% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Rosty Raykov sold 10,349 shares of the business’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $7.76, for a total transaction of $80,308.24. Following the completion of the sale, the director directly owned 98,477 shares of the company’s stock, valued at approximately $764,181.52. The trade was a 9.51% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 11.76% of the company’s stock.

Institutional Investors Weigh In On Adherex Technologies

A hedge fund recently bought a new stake in Adherex Technologies stock. Jane Street Group LLC bought a new stake in shares of Adherex Technologies Inc. (NASDAQ:FENC) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 14,718 shares of the company’s stock, valued at approximately $90,000. Jane Street Group LLC owned about 0.05% of Adherex Technologies at the end of the most recent reporting period. Institutional investors and hedge funds own 55.51% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. Piper Sandler initiated coverage on shares of Adherex Technologies in a research note on Friday, January 9th. They issued an “overweight” rating and a $18.00 target price for the company. Zacks Research raised Adherex Technologies from a “strong sell” rating to a “hold” rating in a research report on Friday, December 12th. B. Riley Financial assumed coverage on shares of Adherex Technologies in a report on Thursday, February 12th. They issued a “buy” rating and a $16.00 price objective on the stock. Wall Street Zen raised Adherex Technologies from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 14th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Adherex Technologies in a research report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $14.80.

About Adherex Technologies

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014. Fennec Pharmaceuticals Inc was founded in 1996 and is based in Research Triangle Park, North Carolina.